These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12181738)

  • 1. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
    Mastroberardino PG; Iannicola C; Nardacci R; Bernassola F; De Laurenzi V; Melino G; Moreno S; Pavone F; Oliverio S; Fesus L; Piacentini M
    Cell Death Differ; 2002 Sep; 9(9):873-80. PubMed ID: 12181738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD; Johnson GV
    Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase is increased in Huntington's disease brain.
    Lesort M; Chun W; Johnson GV; Ferrante RJ
    J Neurochem; 1999 Nov; 73(5):2018-27. PubMed ID: 10537061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D; Reim K; Brose N; Morton AJ
    Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A; Jacobs P; Morton AJ
    Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice.
    Sarang Z; Molnár P; Németh T; Gomba S; Kardon T; Melino G; Cotecchia S; Fésüs L; Szondy Z
    Hepatology; 2005 Sep; 42(3):578-87. PubMed ID: 16108039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
    Menalled LB; Kudwa AE; Oakeshott S; Farrar A; Paterson N; Filippov I; Miller S; Kwan M; Olsen M; Beltran J; Torello J; Fitzpatrick J; Mushlin R; Cox K; McConnell K; Mazzella M; He D; Osborne GF; Al-Nackkash R; Bates GP; Tuunanen P; Lehtimaki K; Brunner D; Ghavami A; Ramboz S; Park L; Macdonald D; Munoz-Sanjuan I; Howland D
    PLoS One; 2014; 9(6):e99520. PubMed ID: 24955833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
    Freeman W; Morton AJ
    Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment.
    Lazic SE; Grote HE; Blakemore C; Hannan AJ; van Dellen A; Phillips W; Barker RA
    Eur J Neurosci; 2006 Apr; 23(7):1829-38. PubMed ID: 16623840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
    Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
    Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
    Prime ME; Andersen OA; Barker JJ; Brooks MA; Cheng RK; Toogood-Johnson I; Courtney SM; Brookfield FA; Yarnold CJ; Marston RW; Johnson PD; Johnsen SF; Palfrey JJ; Vaidya D; Erfan S; Ichihara O; Felicetti B; Palan S; Pedret-Dunn A; Schaertl S; Sternberger I; Ebneth A; Scheel A; Winkler D; Toledo-Sherman L; Beconi M; Macdonald D; Muñoz-Sanjuan I; Dominguez C; Wityak J
    J Med Chem; 2012 Feb; 55(3):1021-46. PubMed ID: 22224594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease.
    Tallaksen-Greene SJ; Janiszewska A; Benton K; Hou G; Dick R; Brewer GJ; Albin RL
    Neurosci Lett; 2009 Mar; 452(1):60-2. PubMed ID: 19429000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
    Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
    Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
    Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
    Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
    Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
    Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement.
    Strnad P; Harada M; Siegel M; Terkeltaub RA; Graham RM; Khosla C; Omary MB
    Gastroenterology; 2007 Apr; 132(4):1515-26. PubMed ID: 17408647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
    Papalexi E; Persson A; Björkqvist M; Petersén A; Woodman B; Bates GP; Sundler F; Mulder H; Brundin P; Popovic N
    Eur J Neurosci; 2005 Sep; 22(6):1541-6. PubMed ID: 16190907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.